STOCK TITAN

Accuray Incorp - ARAY STOCK NEWS

Welcome to our dedicated page for Accuray Incorp news (Ticker: ARAY), a resource for investors and traders seeking the latest updates and insights on Accuray Incorp stock.

Accuray Incorporated (NASDAQ: ARAY) pioneers precision radiation therapy systems that redefine cancer treatment standards. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical advancements, and strategic initiatives shaping the future of radiation oncology.

Track all essential updates in one place, including earnings announcements, regulatory milestones, and technological breakthroughs related to flagship platforms like CyberKnife and Radixact. Our curated feed simplifies monitoring of partnership agreements, research collaborations, and market expansion efforts critical to understanding Accuray's position in medical technology.

Discover comprehensive coverage of operational updates, leadership changes, and product enhancements that impact clinical workflows and patient outcomes. The resource is designed to help stakeholders assess Accuray's progress in developing adaptive radiotherapy solutions with real-time tumor tracking capabilities.

Bookmark this page for streamlined access to verified information about ARAY, including innovation roadmaps and quality control certifications. Check regularly for objective reporting on developments influencing radiation oncology practices worldwide.

Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) has appointed Byron C. Scott, M.D., MBA, to its Board of Directors as of February 12, 2021. Dr. Scott is a renowned physician executive with extensive experience in healthcare analytics and technology. Currently, he teaches at the University of Massachusetts and Jefferson University. His previous roles include Deputy Chief Health Officer at IBM Watson Health and leadership positions at Truven Health Analytics and EmCare. The appointment aims to strengthen Accuray's management team amid evolving radiation therapy market demands.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
management
-
Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) will participate in BTIG's Virtual MedTech Conference on February 18 at 12:30 PM Pacific time. The management team will engage in a Fireside Chat, which can be accessed live via the Accuray website. This event aims to connect more than 100 corporate management teams with institutional investors to discuss investment opportunities and sector trends in the healthcare space. Accuray is dedicated to improving lives through advanced radiation therapy solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
conferences
-
Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) reported its fiscal Q2 2021 results, with net revenue of $97.5 million, slightly down from $98.8 million year-over-year. The company achieved gross orders of $75.4 million, increasing backlog by 11% to $596.2 million. GAAP net income was $4.8 million or $0.05 per share, a decline from $10.7 million in the prior year due to a non-cash gain. Adjusted EBITDA rose to $13.5 million from $7.1 million. The company did not provide fiscal 2021 guidance due to COVID-19 uncertainties.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) announced promising results from a phase II trial involving 338 women with low-risk breast cancer. Seven years after receiving once-daily accelerated partial breast irradiation (APBI) with the TomoTherapy System, 98.8% achieved local disease control. The study, published in the International Journal of Radiation Oncology*Biology*Physics, found minimal acute and late toxicities. Key findings include 99.4% ipsilateral breast tumor recurrence-free control at 76 months and excellent patient-reported outcomes regarding breast appearance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags
none
-
Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) will announce its financial results for the second quarter of fiscal year 2021, ending December 31, 2020, on January 27, 2021, after market close. A conference call is scheduled for the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss these results. Investors can participate via dial-in or listen to a live webcast available on the Company's Investor Relations website. A replay of the call will also be accessible for one week following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
conferences earnings
-
Rhea-AI Summary

Accuray Incorporated (Nasdaq: ARAY) will participate in the 39th J.P. Morgan Annual Healthcare Conference on January 14, 2021, at 11:00 am Pacific / 2:00 pm Eastern. Josh Levine, President and CEO, is set to present. The presentation can be accessed on Accuray's official website post-event. Institutional investors are invited to arrange one-on-one virtual meetings with senior management during the conference. Accuray is dedicated to advancing radiation therapy solutions for complex medical cases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.93%
Tags
conferences
Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) has received 510(k) clearance from the FDA for its ClearRT™ Helical kVCT Imaging. Integrated with the Radixact® System, this advanced imaging solution enhances diagnostic quality, enabling faster patient setup and improved treatment accuracy. Scheduled for commercial release in Spring 2021, ClearRT offers superior image quality and versatility, providing essential support for radiation therapy. Accuray aims to meet the diverse needs of patients while maintaining a high standard of care with this innovative technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.41%
Tags
none
-
Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) announced inducement awards for new Senior Vice President, Quality & Regulatory Affairs, Jim Dennison. Effective November 30, Dennison will receive 56,053 restricted stock units and a stock option for 105,485 shares at an exercise price of $4.46. The awards are not part of the current equity plan but follow guidelines similar to those in the 2016 Equity Incentive Plan. Restricted stock units will vest annually, while the stock option will vest 25% after one year and monthly thereafter, contingent on Dennison's ongoing service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.42%
Tags
none
-
Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) and DHL Supply Chain have formed a global service parts logistics partnership aimed at enhancing Accuray's supply chain and customer service capabilities. This collaboration, effective February 2021, will create a dedicated logistics network across 34 warehousing sites in 16 countries, ensuring medical teams have reliable access to critical radiotherapy technologies. DHL's Control Centers in Columbus, Budapest, and Singapore will provide 24/7 operational support, while advanced software tools will enhance inventory management.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
none
Rhea-AI Summary

Accuray has appointed Jim Dennison as senior vice president of global quality and regulatory affairs, effective immediately. Dennison, with nearly 15 years at GE Healthcare, will oversee quality, regulatory, and government affairs, reporting to Joshua H. Levine, CEO. His previous experience includes managing global design and manufacturing sites, standardizing quality systems, and improving FDA submission processes. Accuray expresses confidence in Dennison's ability to advance quality and regulatory functions to support R&D investments and market expansion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.49%
Tags
management
Accuray Incorp

Nasdaq:ARAY

ARAY Rankings

ARAY Stock Data

152.19M
100.18M
2.53%
60.86%
4.18%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MADISON